LC
TEVA icon

Lourd Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Lourd Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,373
Closed -$288K – 337
2018
Q3 		$288K Buy
13,373
+352
+3% +$8.17K 0.02% 221
2018
Q2 		$317K Sell
13,021
-287
-2% -$5.85K 0.04% 95
2018
Q1 		$227K Buy
13,308
+310
+2% +$6.05K 0.03% 114
2017
Q4 		$246K Buy
+12,998
New +$196K 0.02% 287

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Lourd Capital's TEVA Position: Q4 2018 in Review

Lourd Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 13,373 shares — an estimated $288K sold.

Lourd Capital first reported a position in TEVA in Q4 2017 and held it in 4 quarters. The position peaked at $317K in Q2 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Lourd Capital reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Lourd Capital sold 13,373 Teva Pharmaceuticals shares in Q4 2018, an estimated $288K.
  • Lourd Capital first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Lourd Capital's Teva Pharmaceuticals position peaked at $317K in Q2 2018.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Lourd Capital's 13F filing for Q4 2018, filed 17 Jan 2019.